Vanessa L. Ford

Array ( [id] => 17945769 [patent_doc_number] => 20220332786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/628577 [patent_app_country] => US [patent_app_date] => 2020-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17628577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897070 [patent_doc_number] => 20220306732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => MODIFIED DOSING OF VEGF INHIBITORS FOR OPHTHALMIC USE [patent_app_type] => utility [patent_app_number] => 17/638966 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17897070 [patent_doc_number] => 20220306732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => MODIFIED DOSING OF VEGF INHIBITORS FOR OPHTHALMIC USE [patent_app_type] => utility [patent_app_number] => 17/638966 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17911382 [patent_doc_number] => 20220313777 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => INHALED DELIVERY OF PEPTIDE MIMICS OF CXCL10 FOR TARGETED ANTI-FIBROTIC THERAPY [patent_app_type] => utility [patent_app_number] => 17/641955 [patent_app_country] => US [patent_app_date] => 2020-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830094 [patent_doc_number] => 20220267398 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION [patent_app_type] => utility [patent_app_number] => 17/596277 [patent_app_country] => US [patent_app_date] => 2020-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67665 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17596277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16087061 [patent_doc_number] => 20200197517 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody [patent_app_type] => utility [patent_app_number] => 16/717055 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16717055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15649683 [patent_doc_number] => 20200087371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => USE OF RELAXIN TO TREAT ATRIAL FIBRILLATION [patent_app_type] => utility [patent_app_number] => 16/509239 [patent_app_country] => US [patent_app_date] => 2019-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16509239 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432459 [patent_doc_number] => 20200030412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => IL-12 COMPOSITIONS AND METHODS OF USE IN HEMATOPOIETIC RECOVERY [patent_app_type] => utility [patent_app_number] => 16/291999 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13774765 [patent_doc_number] => 20190000921 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => SEMAPHORIN 3A FOR TREATMENT AND PROGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS [patent_app_type] => utility [patent_app_number] => 16/131491 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16131491 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13870743 [patent_doc_number] => 20190031712 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates [patent_app_type] => utility [patent_app_number] => 16/023005 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023005 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864901 [patent_doc_number] => 20190282692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => SELECTIVE LOCAL INHIBITION OF TNFR1-MEDIATED FUNCTIONS AT THE SITE OF ANTIGEN/ALLERGEN PRESENTATION [patent_app_type] => utility [patent_app_number] => 15/921945 [patent_app_country] => US [patent_app_date] => 2018-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47124 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15921945 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311431 [patent_doc_number] => 20180207252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 15/917098 [patent_app_country] => US [patent_app_date] => 2018-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15917098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413217 [patent_doc_number] => 20180258151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/910165 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15910165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311461 [patent_doc_number] => 20180207267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFB1 INHIBITORS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/863564 [patent_app_country] => US [patent_app_date] => 2018-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15863564 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15646703 [patent_doc_number] => 20200085881 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => TISSUE HEALING AGENT [patent_app_type] => utility [patent_app_number] => 16/469710 [patent_app_country] => US [patent_app_date] => 2017-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6025 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16469710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680998 [patent_doc_number] => 20180118832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => COMBINATION THERAPY FOR CANCER [patent_app_type] => utility [patent_app_number] => 15/674655 [patent_app_country] => US [patent_app_date] => 2017-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19164 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15674655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14893861 [patent_doc_number] => 20190290696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => HUMAN PLATELET LYSATE DERIVED EXTRACELLULAR VESICLES FOR USE IN MEDICINE [patent_app_type] => utility [patent_app_number] => 16/307208 [patent_app_country] => US [patent_app_date] => 2017-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13187 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16307208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11512982 [patent_doc_number] => 20170080056 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-23 [patent_title] => 'SATIATION PEPTIDE ADMINISTRATION' [patent_app_type] => utility [patent_app_number] => 15/271369 [patent_app_country] => US [patent_app_date] => 2016-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 4857 [patent_no_of_claims] => 51 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15271369 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13410203 [patent_doc_number] => 20180256644 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => TUNABLE VARIANT IMMUNOGLOBULIN SUPERFAMILY DOMAINS AND ENGINEERED CELL THERAPY [patent_app_type] => utility [patent_app_number] => 15/759812 [patent_app_country] => US [patent_app_date] => 2016-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -87 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15759812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11364075 [patent_doc_number] => 20170002057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'COMPOSITIONS CONTAINING FUSION PROTEIN OF ALBUMIN AND ANALOGS THEREOF, METHODS FOR MAKING AND USING THE SAME' [patent_app_type] => utility [patent_app_number] => 15/249346 [patent_app_country] => US [patent_app_date] => 2016-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9532 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15249346 [rel_patent_id] =>[rel_patent_doc_number] =>)